The RIQAS Anti-SARS-CoV-2 EQA programme comprises IgG, IgM and total antibodies. This programme uniquely supports both qualitative and quantitative reporting.
Liquid ready-to-use
100% human plasma provides a commutable sample matrix
Monthly reporting – 1 sample per month
Submit results and view reports online via RIQAS.Net
Qualitative and Quantitative reporting options available
Rapid report turnaround allows any necessary corrective actions to be made with minimal disruption
Allows comparison of different methodologies